Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways

Competing Interest Statement

J.H.V. has sponsored research agreements with Biogen. L.H.v.d.B receives personal fees from Cytokinetics, outside the submitted work. A.A-C. has served on scientific advisory boards for Mitsubishi Tanabe Pharma, OrionPharma, Biogen Idec, Lilly, GSK, Apellis, Amylyx, and Wave Therapeutics. A.C. serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Denali, and Cytokinetics.

Funding Statement

E.H. and J.M. were supported by Medical Research Council (MRC) grant K013807 (awarded to J.M.). G.S. was supported by a PhD studentship from the Alzheimer's Society. W.v.R. is supported by funding provided by the Dutch Research Council (NWO) [VENI scheme grant 09150161810018] and Prinses Beatrix Spierfond (neuromuscular fellowship grant W.F19-03). J.J.F.A.v.V. and J.H.V. acknowledge the Prinses Beatrix Spierfonds (W.OR20-08) for funding. A.A.K. is funded by The Motor Neurone Disease Association (MNDA) and NIHR Maudsley Biomedical Research Centre. A.N.B. is grateful to Suna and Inan Kirac Foundation and Koc University for the excellent research environment created and for their financial support. G.A.R. is supported by the Canadian Institutes of Health. J.P.R. is funded by the Canadian Institutes of Health Research (FRN 159279). R.J.P. is funded through the Gravitation program of the Dutch Ministry of Education, Culture, and Science and the Netherlands Organization for Scientific Research (BRAINSCAPES). V.S. is supported by the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. K.P.K. is supported by funding provided by the Dutch Research Council (NWO) [VIDI grant 91719350]. D.B., E.T. and H.R. are employees of Biogen. L.H.v.d.B. reports grants from the Netherlands ALS Foundation, grants from The Netherlands Organization for Health Research and Development (Vici scheme), grants from The European Community's Health Seventh Framework Programme (grant agreement n° 259867 (EuroMOTOR)), grants from The Netherlands Organization for Health Research and Development) the STRENGTH project, funded through the EU Joint Programme - Neurodegenerative Disease Research, JPND), during the conduct of the study. Several authors of this publication are members of the Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases EURO-NMD. Project MinE Belgium was supported by a grant from IWT (n° 140935), the ALS Liga België, the National Lottery of Belgium and the KU Leuven Opening the Future Fund. PVD holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, the ALS Liga België and the KU Leuven funds "Een Hart voor ALS", "Laeversfonds voor ALS Onderzoek" and the "Valéry Perrier Race against ALS Fund". French ALS patients of the Pitié-Salpêtrière hospital (Paris) have been collected with ARSla funding support. This work was supported by the Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata, grant RF-2016-02362405), the Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research (grant 2017SNW5MB); the European Commission's Health Seventh Framework Programme (FP7/2007-2013 under grant agreement 259867), and the Joint Programme-Neurodegenerative Disease Research (Strength, ALS-Care and Brain-Mend projects), granted by Italian Ministry of Education, University and Research. This study was performed under the Department of Excellence grant of the Italian Ministry of Education, University and Research to the "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Italy. We acknowledge funding from the Australian National Health and Medical Research (NHMRC) Council: 1151854, 1083187, 1173790, 1078901, 1113400, 1095215, 1176913 Enabling Grant #402703. Additional funding was provided by the Motor Neurone Disease Research Institute of Australia Ice Bucket Challenge grant for the SALSA-SGC consortium. The Older Australian Twins Study (OATS, used for controls) was facilitated through Twins Research Australia, a national resource in part supported by a Centre for Research Excellence from the Australian National Health and Medical Research Council (NHMRC 1079102). Funding for this study was awarded by the (NHMRC)/Australian Research Council Strategic Award (Grant 401162) and NHMRC grants (1405325, 1024224, 1025243, 1045325, 1085606, 568969, 1093083). We acknowledge the OATS research team: https://cheba.unsw.edu.au/project/older-australian-twins-study. We thank the participants and their informants for their time and generosity in contributing to this research. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement n° 772376 - EScORIAL. The collaboration project is co-funded by the PPP Allowance made available by Health∼Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. This study was supported by the ALS Foundation Netherlands. This is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (United Kingdom, Medical Research Council (MR/L501529/1; MR/R024804/1) and Economic and Social Research Council (ES/L008238/1)) and through the Motor Neurone Disease Association. This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. A.A-C. is supported by an NIHR Senior Investigator Award. Samples used in this research were entirely/in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust. We would like to thank people with MND and their families for their participation in this project. We acknowledge sample management undertaken by Biobanking Solutions funded by the Medical Research Council at the Centre for Integrated Genomic Medical Research, University of Manchester.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All patients and control subjects gave written informed consent and the relevant institutional review boards approved this study. The local data access and ethical committee who approved collection and use of (epi)genetic data are shown below: The Netherlands: University Medical Center Utrecht Medical Ethics Committee, Utrecht, Netherlands. UK MNDA Biobank: Trent University Medical Ethics Committee UK (Sheffield): Yorkshire and the Humber - Sheffield Research Ethics Committee Turkey: Ethics Committee on Research with Human Participants (INAREK) at Bogazici University, Istanbul, Turkey. Belgium: Ethical Committee of University Hospital Leuven Ireland: Beaumont Hospital Research & Ethics Committee Spain (Madrid): Comité de ética de la Investigación del Hospital Carlos III Spain (Barcelona): Bellvitge University Hospital Ethics Committee, Barcelona, Spain. United States: Committee for the Protection of Human Subjects in Research of the University of Massachusetts Medical School, Worcester, USA France (Paris): Medical Research Ethics Committee of "Assistance Publique-Hôpitaux de Paris" France (Tours): The ethics committee of Tours Hospital, France. France (Limoges): Ethics committee of Limoges University Hospital, France. Sweden: Regional Ethical Review Board in Umeå Israel (Tel-aviv): The Institutional Review Board of Tel Aviv Sourasky Medical Center, Israel Israel (Jerusalem): Hadassah University Hospital IRB board Portugal: The Local Research Ethics Committee at the Faculty of Medicine, University of Lisbon, Lisbon, Portugal Italy: Ethical Committee of Città della Salute Hospital, Torino, Italy Switzerland: Kantonale Ethikkomission des Kantons St. Gallen, Switzerland Australia: Sydney South West Area Health Service Human Research Ethics Committee; HREC at the different sites: University of Sydney, Western Sydney Local Health District, Royal Brisbane and Women Hospital Metro North, South Metropolitan Health Service, Macquarie University, QIMR Berghofer Medical Research Institute, University of New South Wales and the University of Melbourne

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes